<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909554</url>
  </required_header>
  <id_info>
    <org_study_id>20210504</org_study_id>
    <nct_id>NCT04909554</nct_id>
  </id_info>
  <brief_title>MRI-based Approaches for Multi-omics Model to Early Predict Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer</brief_title>
  <official_title>An MRI-based, Multi-omics Model for Early Prediction of Pathologic Response After the First Cycle of Neoadjuvant Chemotherapy in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research is to evaluate the accuracy of a multi-omics model&#xD;
      based on magnetic resonance imaging (MRI) in predicting pathologic response after the first&#xD;
      cycle of neoadjuvant chemotherapy given to patients with locally advanced breast cancer, thus&#xD;
      allowing early chemotherapy regimen modification to increase number of patients achieving&#xD;
      pathological complete response or save patients from toxic effects of ineffective&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of the MRI-based multi-omics model in evaluating tumor response</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <description>defined as the model's capability of accurately identifying patients who will achieve pathological complete response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity of the MRI-based multi-omics model in evaluating tumor response</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <description>defined as the model's capability of accurately identifying patients who will not achieve pathological complete response</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Selection of patients diagnosed with breast cancer and treated with neo-adjuvant&#xD;
        chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥18 years.&#xD;
&#xD;
          -  Histologically confirmed invasive breast carcinoma&#xD;
&#xD;
          -  Clinical stage II-III at presentation&#xD;
&#xD;
          -  Scheduled for neoadjuvant chemotherapy&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received any prior chemotherapy, radiation therapy or endocrine&#xD;
             therapy for their current breast cancer.&#xD;
&#xD;
          -  Patients with any general contraindication to MRI.&#xD;
&#xD;
          -  Patient with breast cancer who are not eligible for NAC (pregnant patients,&#xD;
             multicentric breast cancer, metastatic breast cancer).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kun Wang, MD</last_name>
    <phone>020-83827812</phone>
    <email>gzwangkun@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanqi Chen</last_name>
    <phone>13798818919</phone>
    <email>chen13798818919@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun Wang, MD</last_name>
      <phone>02083827812</phone>
      <email>gzwangkun@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Kun Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imaging (MRI)</keyword>
  <keyword>Neoadjuvant chemotherapy (NAC)</keyword>
  <keyword>therapeutic response</keyword>
  <keyword>breast cancer</keyword>
  <keyword>early prediction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

